Buddy Hield (Sacramento Kings) with an and one vs the Washington Wizards, 04/14/2021
Buddy Hield (Sacramento Kings) with an and one vs the Washington Wizards, 04/14/2021
Robert Saleh wrapped up his first practice with the New York Jets by taking his usual spot behind the huddle and waiting for the head coach to address the team. “Oh, shoot,” Saleh said Friday with a big grin and laugh. Guard Alijah Vera-Tucker, taken with the 14th overall pick from USC, said Saleh's energy was evident from the moment he met him in person last week.
JACKSONVILLE, Fla., May 07, 2021 (GLOBE NEWSWIRE) -- Today, the Board of Directors of CSX Corp. (NASDAQ: CSX) approved a $0.28 per share quarterly dividend on the company's common stock. The dividend is payable on June 15, 2021, to shareholders of record at the close of business on May 31, 2021. About CSX and its Disclosures CSX, based in Jacksonville, Florida, is a premier transportation company. It provides rail, intermodal and rail-to-truck transload services and solutions to customers across a broad array of markets, including energy, industrial, construction, agricultural, and consumer products. For nearly 200 years, CSX has played a critical role in the nation's economic expansion and industrial development. Its network connects every major metropolitan area in the eastern United States, where nearly two-thirds of the nation's population resides. It also links more than 230 short-line railroads and more than 70 ocean, river and lake ports with major population centers and farming towns alike. This announcement, as well as additional financial information, is available on the company's website at http://investors.csx.com. CSX also uses social media channels to communicate information about the company. Although social media channels are not intended to be the primary method of disclosure for material information, it is possible that certain information CSX posts on social media could be deemed to be material. Therefore, we encourage investors, the media, and others interested in the company to review the information we post on Twitter (http://twitter.com/CSX) and on Facebook (http://www.facebook.com/OfficialCSX). The social media channels used by CSX may be updated from time to time. More information about CSX Corporation and its subsidiaries is available at www.csx.com. Contact:Bill Slater, Investor Relations904-359-1334 Bryan Tucker, Corporate Communications855-955-6397
While some technology stocks got a boost Friday after a disappointing U.S. jobs report, some portfolio managers say that blow-out earnings from several large technology companies over the last few weeks are not enough to keep making outsized bets on the sector. Instead, those fund managers say that they are continuing to rotate into value and cyclical stocks - whose fortunes are closely tied to economic conditions - in anticipation that the economic recovery will be longer and more gradual than originally anticipated. The notion that the U.S. jobs recovery has not yet peaked was reinforced by data from the Labor Department on Friday that showed U.S. employers hired far fewer workers than anticipated.
The Run-DMC rapper tells PEOPLE about how the Felix Organization is continuing to change young lives
The S&P 500 and the Dow hit record highs on Friday, while megacap growth stocks drove a recovery on Nasdaq after U.S. jobs data eased concerns over prospects for rising rates. U.S. job growth unexpectedly slowed in April, likely restrained by shortages of workers, the Labor Department report on Friday showed. The report alleviated some concerns about rising inflation and potentially higher U.S. interest rates, which some investors worry would hurt growth companies with high valuations.
TORONTO — The Ontario Securities Commission says it moving to ban deferred sales charges on mutual funds in the province. The securities regulator says the policy it is preparing will prohibit the payment of upfront sales commissions by fund organizations to dealers and mirror policies in other provinces. Deferred sales charges are paid by investors when they pull money out of mutual funds before a set date. Controversy has surrounded funds with such fees because advisers earn upfront commission higher than they would on other types of mutual funds, potentially incentivizing them to push DSC funds over ones with lower costs. The Canadian Securities Administrators announced a ban on such charges last year, but the OSC did not follow suit and does not expect its new policy to take effect until next June. The OSC says it wants to adopt a ban because the idea received support from stakeholders and recent advances in innovation have provided investors with more affordable and transparent products and advice. This report by The Canadian Press was first published May 7, 2021. The Canadian Press
TORONTO, May 07, 2021 (GLOBE NEWSWIRE) -- Sprott Inc. (“Sprott”) (NYSE/TSX: SII) announced today the results of its Annual Meeting of shareholders held on May 7, 2021 (the “Meeting”). Sprott is pleased to announce that all resolutions put forward in the Management Information Circular dated March 22, 2021 (the “Circular”) to its shareholders were approved. Results of the matters voted on at the Meeting are set out below. Election of Directors Sprott’s six director nominees were elected: NomineeVotes For (percent)Votes Withheld (percent)Ronald Dewhurst99.041%0.959%Graham Birch99.553%0.447%Peter Grosskopf99.460%0.540%Sharon Ranson97.598%2.402%Arthur Richards Rule IV99.122%0.878%Rosemary Zigrossi87.970%12.030% Appointment of Auditors KPMG LLP, Chartered Accountants, was re-appointed as auditor of Sprott and the board of directors of Sprott were authorized to fix the auditors’ remuneration and terms of engagement. Votes For (percent): 99.814% Votes Withheld (percent): 0.186% For further details on each of the above matters, please refer to the Circular available under Sprott’s profile on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com. Final voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com. About Sprott Sprott is a global leader in precious metal investments. With offices in Toronto, New York, and London, Sprott is dedicated to providing investors with specialized investment strategies that include Exchange Listed Products, Managed Equities, Lending, and Brokerage. Sprott’s common shares are listed on the New York Stock Exchange under the symbol (NYSE:SII) and on the Toronto Stock Exchange under the symbol (TSX:SII). For more information, please visit www.sprott.com. FOR FURTHER INFORMATION: Investor Contact Information: Glen WilliamsManaging Director(416) email@example.com
SmartMetric, Inc. (OTCQB: SMME): SmartMetric has invented a hardware and software solution that detects whether or not the finger being used to activate the card is from an actual person or not.
MONTREAL, May 07, 2021 (GLOBE NEWSWIRE) -- Senvest Capital Inc. today reported a net income attributable to common shareholders of $574.5 million or $224.27 diluted earnings per share for the three months ended March 31, 2021. This compares to a net loss attributable to common shareholders of ($342) million or ($129.38) diluted loss per share for the same period in 2020. Financial statements are available online at Sedar www.sedar.com CONSOLIDATED STATEMENTS OF INCOME (LOSS) (in millions of dollars, except per share amounts) For the three months ended March 31, 2021 March 31, 2020 Net income (loss) attributable to common shareholders $574.5 ($342) Diluted earnings (loss) per share attributable to common shareholders $224.27($120.38) Contact: George Malikotsis, Vice President Finance(514) 281-8082
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock. The stock options are exercisable at a price of $30.37 per share, the closing price of Albireo’s common stock on May 4, 2021, the grant date, and were granted as inducements material to the employee’s acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has a 10-year term and vests over a four-year period, subject to the employee’s continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employee’s start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The stock options are subject to the terms and conditions of Albireo’s 2020 Inducement Equity Incentive Plan. About AlbireoAlbireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product candidate, Bylvay, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 trials in PFIC, Alagille syndrome and biliary atresia. For PFIC, the FDA recently granted Priority Review and set a PDUFA goal date of July 20, 2021. In Europe, the EMA validated MAA. Bylvay is the only IBATi granted accelerated assessment by the EMA. Bylvay has been provisionally accepted by both the FDA and EMA as the brand name for odevixibat. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com. Media & Investor contacts:Colleen Alabiso, 857-356-3905, firstname.lastname@example.org Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 229,931 restricted stock units of Atara’s common stock to 47 newly hired employees and stock options to purchase an aggregate of 206,167 shares of Atara’s common stock to 15 such newly hired employees. These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of May 3, 2021, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
WINSTON-SALEM, N.C. (AP) — A man found dead after a house fire and standoff with police died from a gunshot wound received during a shootout with officers, investigators in North Carolina said. The North Carolina Medical Examiner’s Officer found that Edwin Castillo, 34, died from a gunshot wound, Winston-Salem police said in a release Thursday. An officer called to a home Wednesday afternoon for a report of “unknown trouble” found Castillo unconscious in the doorway and called for a medic, police said.
PHOENIX, May 07, 2021 (GLOBE NEWSWIRE) -- WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini Holdings” or the “Company”) (Nasdaq: WSC), a North American leader in turnkey modular space and portable storage solutions, today announced that Brad Soultz, Chief Executive Officer, Tim Boswell, Chief Financial Officer and Nick Girardi, Director of Treasury & Investor Relations, will host virtual private meetings during the Morgan Stanley Business Services Conference on Thursday, May 13, 2021. The meetings will be held by appointment only. About WillScot Mobile Mini Holdings WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible workspace and portable storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 275 branch locations and additional drop lots throughout the United States, Canada, Mexico, and the United Kingdom. Additional Information and Where to Find It Additional information can be found on the company’s website at www.willscotmobilemini.com Contact Information Investor Inquiries: Nick Girardinick.email@example.com Media Inquiries: Scott Junkscott.firstname.lastname@example.org
RESEARCH TRIANGLE PARK, N.C., May 07, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 40,000 shares of G1’s common stock to five employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”). The stock options were granted as an inducement material to the new employee’s becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with G1, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The stock options are exercisable at a price of $20.86 per share, the closing price of G1’s common stock on May 3, 2021, the grant date. Each stock option has up to a ten-year term and vests over four years, with 25% of the award vesting on the first anniversary of the employee’s employment, and as to an additional 1/48th of the shares monthly thereafter, subject to continued service through the applicable vesting dates (subject to the terms and conditions of the stock option agreement covering the grant). The stock options are subject to the terms and conditions of the Inducement Plan. About G1 TherapeuticsG1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics. G1 Therapeutics™ and the G1 Therapeutics logo are trademarks of G1 Therapeutics, Inc. Contact: Will RobertsG1 Therapeutics, Inc.Vice President, Investor Relations and Corporate Communications(919) 907-1944 email@example.com
Saul ‘Canelo’ Alvarez has already defeated six British fighters.
Recipes for Ramadan: three sweets for Eid from maamoul biscuits to turshana. These dessert recipes are all inspired by the authors’ mothers, drawing on traditions from Japan to Iraq
The Scientists, L-Fresh the Lion, Holiday Sidewinder: Australia’s best new music for May. Each month we add 20 new songs to our Spotify playlist. Read about 10 of our favourites here – and subscribe on Spotify, which updates with the full list at the start of each month
Tokyo ramps up for Olympics but winners will be scarce if Games go ahead. In less than three months’ time, the city will welcome about 11,000 athletes and perhaps double that number of staff, coaches and journalists. Plus, almost inevitably, Covid-19
Labor renews calls for national integrity commission over Sydney airport offsets. Mark Dreyfus says corruption watchdog needed to investigate government buying $30m in offsets related to new airport
I met my first Australian sea lion 57 years ago. Today I fear for this delightful animal. I’ve seen sea lion populations decimated. I want people to understand how wonderful an unafraid wild creature can be